Core Business

  

Biopharma CDMO Services

  
Website

KriSan Biotech

Founded in 2015, KriSan Biotech specializes in complex drug process development and GMP production. With over 20 years of expertise developing novel drug processes, KriSan’s core competency lies in Complex Small Molecules, peptides, oligonucleotides, antibody-drug conjugates (ADC), and peptide-drug conjugates (PDC).
KriSan provides exceptional and customer-oriented services throughout the new drug development cycle, including process development, scale-up, analytical development, stability programs, cGMP production, and regulatory support.
The team adheres to international regulatory and quality standards, and the KriSan facility is certified with PIC/s GMP. KriSan aims to provide worldwide customers with drug substances needed starting from pre-clinical phases and extending all the way to commercialization. The successful delivery of approximately 100 APIs supported 50+ companies in clinical trials across the United States, European, Australia, Japan, Singapore, and Taiwan.
KriSan is a preferred CDMO service partner, and stands as a Total-Solution and One-Stop Shop, poised to meet clients' diverse requirements

Taiwan

News
Date Title
2023-12-05 晟德法說》釋「長線」佳音 展望明年景氣持樂觀看法 Detail
2024-06-25 晟德股東會/承認配發1.5元現金股利 殖利率3.3% 連續24年配發股利 2024年成長充滿信心 續替股東創造最大價值 Detail
2024-07-19 林榮錦打造晟德生技投資帝國 Detail
2025-04-09 晟德與順藥同步啟動庫藏股計畫 強調對營運前景高度信心 Detail
2025-04-29 台日攜手搶攻ADC商機! Detail